Kornimate/medical-research-clean huggingface dataset:
pentoxifylline as an adjuvant therapy in the treatment of pediatric pneumonia; a new perspective of an old drug

Conditions: Pentoxifylline as an Adjunct Therapy in the Treatment of Pneumonia

Summary: pentoxifylline is a xanthine-derived, commercially produced drug approved for the management of intermittent claudication in patients suffering from a chronic occlusive arterial disease of the limbs. pentoxifylline has been documented to display anti-inflammatory and immunomodulatory effects, as well as some antithrombotic and antiviral effects. this drug has also been shown to reduce lung fibrosis in patients with covid-19, as well as to prevent thromboembolic events. this work aims to assess the benefit of oral pentoxifyllin supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community-acquired pneumonia

this is a randomized clinical trial study that will be carried out on 100 children with community-acquired pneumonia admitted to the pulmonology unit, pediatric department. group 1: pentoxifylline group, and group 2: control group

Eligibility criteria:
inclusion criteria: * all children aged 2 months -18 years with community-acquired pneumonia diagnosed by signs and symptoms of cap including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x-ray indicating community-acquired pneumonia exclusion criteria: * children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorders impacting respiration i.e. genetic, metabolic, neuromuscular disorders, and children with chd affecting the pulmonary blood flow.
brain dynamics in response to jugular vein compression

Conditions: Concussion, Mild

Summary: clinical trials have suggested that this device is effective in mitigating changes in brain structure and function in athlete populations. the purpose of the current study is to better understand the underlying mechanistic response of the brain hemodynamics to mild jugular vein compression

significant morbidity, mortality, and related costs are caused by traumatic brain injury (tbi). a simple, effective, and lightweight device worn by athletes or war fighters in the field, designed to mitigate tbi resulting from blast trauma or concussive events, would save lives, and the huge costs currently being experienced for life-treatment of surviving victims. an externally-worn medical device (the device) that applies mild jugular vein compression according to the principle of the queckenstedt maneuver, is being developed by q30 sports science, llc (q30). preliminary research suggests that the device has the potential to reduce the likelihood of tbi. the currently developed collar (smith 2009, smith and fisher 2011, smith and fisher 2011, smith 2012) has been approved for studies in humans (irb 2013-2240) and the results indicate safety for use during high demand and maximal exertion activities. regarding safety, the externally worn collar is meticulously designed to mimic the body's own omohyoid muscle actions upon the jugular veins that will provide similar pressure and volume increases not to surpass that of a yawn or the mere act of just lying down. initial safety testing and early clinical trials indicate that the collar application is both safe and efficacious to prevent brain microstructure and neurophysiological changes in response to head impacts.

Eligibility criteria:
inclusion criteria: * normal healthy volunteer aged 7-40 * able to provide written consent * able to tolerate hypercapnia for 1-2 minutes exclusion criteria: * unable to provide written consent * history of neurological deficits, previous cerebral infarction, or severe head trauma as indicated through pre-season screening: * medical contraindications to restriction of venous outflow via the internal jugular veins (known increased intracerebral pressure, metabolic acidosis or alkalosis) * glaucoma (narrow angle or normal tension) * hydrocephalus * recent penetrating brain trauma (within 6 months) * known carotid hypersensitivity * known increased intracranial pressure * central vein thrombosis * any known airway obstruction * any known seizure disorder
adrenal vein sampling as a tool to identify biomarkers that aid the diagnosis of adrenocortical carcinoma

Conditions: Adrenocortical Carcinoma

Summary: the goal of this observational pilot study is to explore whether we can identify biomarkers predictive for the diagnosis of adrenocortical carcinoma in blood. five participants who are suspected to have adrenocortical carcinoma will undergo an adrenal vein sampling in order to obtain a blood sample from the adrenal vein. this blood sample will be analyzed and compared to blood samples taken from the adrenal vein of 20 control patients, which are patients who do not have adrenocortical carcinoma. the blood samples of the control patients will be drawn during routine medical care.


Eligibility criteria:
inclusion criteria: in order to be eligible to participate in the study group, a subject must meet all of the following criteria: * patient age ≥18 years * high clinical suspicion of adrenocortical carcinoma, based on clinical signs (due to hormonal overproduction), steroid hormone profile and radiological features (e.g. tumor size ≥4cm, inhomogenous aspect and tumor attenuation of hu ≥10) * able to provide signed informed consent in order to be eligible to participate in the control group, a subject must meet all of the following criteria: * patient age ≥18 years * routine diagnostic process includes avs * no suspicion of malignancy * able to provide signed informed consent exclusion criteria: patients are not able to participate if: * they have a known allergy to (iodinated) contrast fluid * they use vitamin k antagonizing anticoagulants or doac's, except for when on the day of the adrenal vein sampling the anticoagulants are already stopped for the following adrenal surgery, and in case of using vitamin k antagonizing anticoagulants the inr is \<3 * the platelet count is below 20 * anatomy of the adrenal vein is not suitable for performing the avs procedure, based on the judgement of an experienced interventional radiologist * contraindications for use of synacthen * they have a known hypersensitivity to any of the substances of synacthen * they are pregnant
changes of visual function, ocular surface structures and physiology after long-termed contact lens wear

Conditions: Ocular Surface Disease; Keratoconus; Irregular Astigmatism

Summary: our study is aimed to observe the long termed effect of contact lens wear on ocular surface, especially focused on visual function and ocular inflammation mediators.

contact lens fitting are important treatments for many ocular diseases as they provide three main therapeutic applications: visual correction, protection of ocular surface, and cosmetic or sport purposes. the ophthalmology department of ntuh has set up contact lens special clinic as one of our comprehensive refractive services. the investigators provided corneal lenses or rose k lenses for optical correction of keratoconus patients; the investigators also fitted large scleral lenses for the correction of irregular astigmatism for post-penetrating keratoplasty and post-refractive surgery patients. in addition, contact lenses can be an adjuvant therapy for ocular surface disorders as severe dry eye and limbal insufficiency. there were researches that proved the inflammatory mediators and neutrophils increased after long-termed wear of silicon hydrogel soft lenses or over night orthokeratology lenses. they also concluded that lens wear affected corneal epithelial proliferation. however, the physiological changes after long-termed wear of large diameter scleral lenses are still pending. in addition, we still do not understand the lens effects on high order aberration and ocular surface structures. the purpose of our study is to analyze the epidemiologic data and treatment results of the patients fitted with specialty lenses in our contact lens clinic from aug 2016 to aug 2018. patients will be categorized into different groups by the diagnoses and the type of lens wear. after 6 months of follow up, the change of visual acuity, visual function related quality of life, the changes of ocular surface structures and physiology will be analyzed. the investigators hope to share the experiences of specialty contact lens fitting and understand the effects of long-term contact lens wear on ocular surface.

Eligibility criteria:
inclusion criteria: * age 20 to 65 * contact lens wear * willing to be followed for at least 6 months exclusion criteria: * active ocular infection * active corneal melting * inability to follow lens cleaning instructions * pregnancy
molecule removal and ease of use: a comparison of two different dialyzers

Conditions: Chronic Kidney Disease

Summary: the polyflux hd-c4 (gambro renal products) is a new dialyzer based on the existing polyflux h membrane and dialyzer technology, but which achieves a performance comparable to polyflux 210h in a significantly smaller device. the objectives of this study are: 1. to compare and contrast small and large molecule removal by the polyflux hd-c4 and polyflux 210h dialyzers under conditions of routine hemodialysis; and, 2. to compare and contrast the ease of use of the polyflux hd-c4 dialyzer with that of the polyflux 210h under conditions of routine clinical use for hemodialysis.


Eligibility criteria:
inclusion criteria: * adults 18 years of age or older * stable hemodialysis prescription using polyflux 210h or polyflux 21r for at least 2 months prior to study enrollment * dialyzing through a native fistula or gore-tex graft. * blood access must be able to provide a blood flow rate of 400 ml/min. exclusion criteria: * non-compliance with dialysis * hematocrit less than 28% * active infection

Keywords: hemodialysis dialysis, renal dialysis, extracorporeal extracorporeal dialysis
the role of near-infrared spectroscopy measurements in determining i̇ntraoperative blood loss in cancer surgery

Conditions: Near-Infrared Spectroscopy; Cancer Surgery

Summary: major cancer surgeries often involve significant intraoperative blood loss and require transfusion. conventional markers, such as hemoglobin (hb) and hematocrit (hct), provide limited insight into tissue oxygenation and transfusion thresholds. near-infrared spectroscopy (nirs) is a non-invasive approach for monitoring regional tissue oxygen saturation and guiding transfusion decisions. this study aimed to evaluate the role of cerebral (cso₂) and peripheral (pso₂) nirs measurements in identifying intraoperative blood loss and determining transfusion thresholds during major cancer surgeries.

this prospective observational study included 65 patients aged 18-75 years who underwent major cancer surgery. cso₂ and pso₂ were monitored at three time points: baseline (t1), pre-transfusion or significant blood loss (t2), and the end of surgery (t3).hemodynamic parameters, acid-base status, hemoglobin levels, estimated blood loss, and transfusion volumes were recorded.patients were divided into transfused (group 1) and non-transfused (group 2) cohorts. statistical analyses included t-tests, mann-whitney u tests, and receiver operating characteristic (roc) analysis.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i-iii * major cancer surgery in the general surgery, urology, and obstetrics and gynecology departments exclusion criteria: * carotid artery stenosis * recent myocardial infarction * history of cerebrovascular events * prior neck surgery, * cervical disc herniation * spinal cord injury, * sudden vision loss, * deep vein thrombosis, * refusal to participate.
access to maternity and risk factors in a non-consultant population (proxima)

Conditions: Post Partum Depression

Summary: characterize the psychic and medical disorders related to pregnancy and motherhood in a group of primiparous and primigratic women.


Eligibility criteria:
inclusion criteria: * primiparous and primigest women, * singleton pregnancy * consultant at the university hospital of besançon in gynecology / obstetrics department - initial consultation * 25 to 45 years old, * european culture and speaking french, * living in a relationship with the spouse * spontaneous pregnancy, without medical help * having agreed to the use of this medical data as part of this research and the completion of the self-questionnaires. * patients who benefit from a social security scheme exclusion criteria: * termination of pregnancy or non-progressive pregnancy * prematurity of the child (childbirth before 37 weeks) * maternal pathologies acquired during pregnancy * fetal diseases acquired during pregnancy * pregnancy of twins or triplets * any type of medical difficulties occurring during pregnancy (gestational diabetes, high blood pressure, threat of preterm delivery, preeclampsia, ...) * any type of difficulty occurring during childbirth for example, hemorrhage of maternal deliverance * birth by cesarean section birth necessitating the use of instruments that led to the transfer of the baby to the neonatology unit or to the kangaroo unit * at birth, baby's apgar less than 7. * fetal death * childbirth that did not occur at the chu maternity ward
oral manifestations in chronic kidney disease.

Conditions: Chronic Kidney Diseases; Hemodyalysis; Pre-dyalisis; Peritoneal Dyalisis

Summary: the goal of this observational study is to investigate oral manifestations in patients with chronic kidney disease (ckd) for early detection, that alterations play an important point for dental guide during the progression and type of treatment of ckd . an oral exam was performed for detection oral manifestations, age, smoking, alcoholic and oral hygiene habits were collected. the study has 3 groups under study: hemodialysis (hd), peritoneal dialysis (pd) and pre-dialysis (p-d)


Eligibility criteria:
inclusion criteria: * age ≥ 18 years and ≤ 80 years; * no change of medication in the last 3 months; * history of ckd comported by data laboratory (grf\<60 ml/min/1.73m²). exclusion criteria: * age ≤ 18 years and ≥ 80 years; * patients undergoing orthodontic therapy; * patients taking drugs; * patients changes the medication or introduced a new medication.
distal transradial access for primary percutaneous coronary intervention in stemi patients

Conditions: Acute ST-segment Elevation Myocardial Infarction; Radial Artery Occlusion; Distal Radial Artery Approach

Summary: the transradial access (tra) is currently the preferred approach for percutaneous coronary intervention (pci). however, in patients with acute st-segment elevation myocardial infarction (stemi) after emergency pci, the high incidence of the radial artery rao limits the future choice of the radial artery for percutaneous intervention. the literature reported that distal transradial access (dtra) significantly reduced rao after elective pci, but the application of dtra in emergency pci in stemi has not been reported. we have completed 126 cases of dtra undergoing emergency pci after stemi, which has been preliminarily confirmed to be safe and effective. a single-center, open, prospective, randomized controlled study is planned to compare the use of dtra and tra in emergency pci in stemi patients. the primary endpoint was the incidence of rao within 24 hours after surgery. this clinical study verified that dtra compared with tra could reduce the rao incidence of stemi patients after emergency pci. the project will explore a new artery approach to reduce rao, and provide a basis for the selection of artery approach in stemi emergency pci patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of stemi * to undergo emergency pci treatment * palpable pulsation of the radial artery and distal radial artery exclusion criteria: * arteriovenous fistula of radial artery and cephalic vein has been performed with regular hemodialysis * suspicious left main block of electrocardiogram * had used the radial artery percutaneous interventional treatment before * cardiogenic shock
discovering laryngomalacia

Conditions: Laryngomalacia

Summary: laryngomalacia is the most common congenital malformation of the larynx. it results from abnormal prolapse of supraglottic structures during inspiration. symptoms usually appear within the first 2 weeks of life. its severity increases in up to 6 months. 15-60% of infants with laryngeomalacia have synchronous airway anomalies.

500 full term babies ≥37 weeks of both sexes delivered by different modes of delivery, with birth weights ≥2.5 kg, no history of natal or post-natal complications and from the same community. mothers of these babies are from different socioeconomic standards and from the same community. these babies were diagnosed as having laryngomalacia. clinical, flexible nasal and laryngeal scope, radiological and milk scintiscan were the tools used in our assessment. one thousand full term babies delivered with normal larynx, almost within the same period of time and from the same community were used as a control. laryngomalacia was recognized with significant statistical difference in dacryostenosis, deviated nasal septum, adenoid hypertrophy and gastroesophageal reflux disease. no significant statistical difference in pectus excavatum, cleft lip or palate, congenital lobar emphysema fistula and choanal atresia.

Eligibility criteria:
inclusion criteria: * 500 full term babies ≥ 37 weeks of both sexes were delivered by different modes of delivery, with birth weights of ≥ 2.5 kg, with no history of natal complications and from the same community. * mothers of these babies are from different socioeconomic standards with different educational levels. exclusion criteria: -

Keywords: laryngomalacia congenital anomalies associated health problems
a study of bgb-21447, a bcl-2 inhibitor, in mature b-cell malignancies

Conditions: Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Relapsed Follicular Lymphoma; Relapsed Marginal Zone Lymphoma; Relapse Diffuse Large B Cell Lymphoma; Relapsed Small Lymphocytic Lymphoma; Refractory Follicular Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Richter Transformation; Refractory Diffuse Large B-cell Lymphoma; Transformed Non-Hodgkin Lymphoma

Summary: this study is testing the safety and tolerability of bgb-21447 monotherapy in participants with relapsed or refractory (r/r) non-hodgkin lymphoma (nhl) and chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll). the study aims to determine the maximum tolerated dose (mtd), maximum administered dose (mad), recommended phase 2 dose (rp2d), and pharmacokinetic profile of the drug. additionally, preliminary antitumor activity will be characterized. the study is divided into 2 main parts: part 1 "monotherapy dose finding" and part 2 "monotherapy dose optimization."


Eligibility criteria:
inclusion criteria 1. confirmed diagnosis (per world health organization \[who\] guidelines, unless otherwise noted) of one of the following: cohort a1 and cohort a2: 1. r/r dlbcl (for cohort a1 and cohort a2.1) * high-grade b-cell lymphomas with translocations of myc and bcl-2 and/or bcl-6 are not allowed in cohort a1 but may be allowed in cohort a2.1 2. r/r fl (for cohort a1 and cohort a2.2) 3. r/r mzl (for cohort a1 and cohort a2.2) 4. transformed b-cell nhl (for cohort a1 only) 5. richter's transformation to dlbcl (for cohort a1 only) 2. measurable disease by computed tomography/magnetic resonance imaging. exclusion criteria: 1. prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized gleason score ≤ 6 prostate cancer or lentigo maligna melanoma that has been curatively resected 2. known central nervous system involvement by lymphoma/leukemia 3. prior autologous stem cell transplant \< 3 months before the first dose of study drug. or prior chimeric antigen receptor t-cell (car-t) therapy \< 3 months before the first dose of study drug 4. prior allogeneic stem cell transplant. 5. major surgery \< 4 weeks before the first dose of study treatment note: other protocol-defined inclusion/exclusion criteria may apply.

Keywords: relapsed non-hodgkin lymphoma refractory non-hodgkin lymphoma relapsed chronic lymphocytic leukemia follicular lymphoma marginal zone lymphoma nhl fl mzl refractory chronic lymphocytic leukemia rcll relapsed follicular lymphoma refractory follicular lymphoma relapsed marginal zone lymphoma refractory marginal zone lymphoma rfl rmzl relapsed small lymphocytic lymphoma refractory small lymphocytic lymphoma rsll richter's transformation rt rr dlbcl bcl-2 bcl-2i
evaluation of an intervention program targeted at improving balance and functional skills after stroke

Conditions: Cerebrovascular Accident; Musculoskeletal Equilibrium

Summary: the purpose of this study is to evaluate a 5-week intervention program targeted at improving balance and functional skills for people with stroke.

many people with stroke experience a deterioration in balance and a functional decline due to hemiplegic muscle strength. this tend to restrict the persons activity in daily life and also leads to a low falls self efficacy. high intensity exercise have shown to be effective for improving strength and balance for older people in general living in residential care facilities. it is interesting to see if this high intensity exercise also is applicable in the older stroke population. comparison: an intervention group receives three training sessions per week and one theory session per week during 5 weeks, compared to a control group that receives one theory session per week during 5 weeks.

Eligibility criteria:
inclusion criteria: * 55 years of age or older * stroke diagnosis 3-6 months prior to inclusion * ability to walk 10 meter with or without assistive device * ability to understand simple instructions exclusion criteria: * tia * independent in walking outdoors * serious visual impairment * serious hearing impairment * long distance to intervention station

Keywords: accidental falls cerebrovascular accident balance adl self efficacy quality of life gait parameters